Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy

Show simple item record

dc.contributor.author Paajanen, Juuso
dc.contributor.author Ilonen, Ilkka
dc.contributor.author Lauri, Helena
dc.contributor.author Järvinen, Tommi
dc.contributor.author Sutinen, Eva
dc.contributor.author Ollila, Hely
dc.contributor.author Rouvinen, Eeva
dc.contributor.author Lemström, Karl
dc.contributor.author Räsänen, Jari
dc.contributor.author Ritvos, Olli
dc.contributor.author Koli, Katri
dc.contributor.author Myllärniemi, Marjukka
dc.date.accessioned 2020-06-04T08:55:01Z
dc.date.available 2020-06-04T08:55:01Z
dc.date.issued 2020-05
dc.identifier.citation Paajanen , J , Ilonen , I , Lauri , H , Järvinen , T , Sutinen , E , Ollila , H , Rouvinen , E , Lemström , K , Räsänen , J , Ritvos , O , Koli , K & Myllärniemi , M 2020 , ' Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy ' , Clinical Lung Cancer , vol. 21 , no. 3 , pp. E142-E150 . https://doi.org/10.1016/j.cllc.2019.10.013
dc.identifier.other PURE: 128043999
dc.identifier.other PURE UUID: 3b70abbf-1a53-4f96-8217-245715c41734
dc.identifier.other RIS: urn:EE798D0E0A061D501CE1DA6B2D5CB764
dc.identifier.other WOS: 000528327300003
dc.identifier.other ORCID: /0000-0001-9343-0867/work/75461970
dc.identifier.other ORCID: /0000-0001-8515-9659/work/75563408
dc.identifier.other ORCID: /0000-0001-6920-4093/work/75563446
dc.identifier.other ORCID: /0000-0002-8149-3550/work/80578787
dc.identifier.uri http://hdl.handle.net/10138/315743
dc.description.abstract Activin A has previously been associated with cancer cachexia and in vitro resistance to platinum-based chemotherapy. We studied circulating activin A concentrations as well as activin B and their antagonists' follistatin/follistatin-like 3 in presurgical patients with non-small-cell lung cancer and malignant pleural mesothelioma. We found that circulating activing A levels were elevated in malignant pleural mesothelioma and associated with cancer cachexia and poor response to platinum-based chemotherapy. Circulating activing A separated non-small-cell lung cancer from benign lung lesion. Background: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed in in vitro resistance to platinum-based chemotherapy. We evaluated circulating activin levels and their endogenous antagonists' follistatin/follistatin-like 3 in intrathoracic tumors. Materials and Methods: Patients suspected of thoracic malignancy were recruited prior to surgery. Serum samples were collected from 21 patients with MPM, 59 patients with non-small-cell lung cancer (NSCLC), and 22 patients with benign lung lesions. Circulating activin/follistatin levels were measured using enzymelinked immunosorbent assay and compared with clinicopathologic parameters. Results: Circulating activin A levels were elevated in patients with MPM when compared with patients with NSCLC or benign lung lesion samples (P <.0001). Also, follistatin and follistatin-like 3 levels were the highest in MPM, although with less difference compared with activin A. Receiver operating characteristic analysis for activin A for separating NSCLC from benign lung lesion showed an area under the curve of 0.856 (95% confidence interval, 0.77-0.94). Activin A levels were higher in patients with cachexia (P <.001). In patients with MPM, activin A levels correlated positively with computed tomographybased baseline tumor size (R = 0.549; P = .010) and the change in tumor size after chemotherapy (R = 0.743; P = .0006). Patients with partial response or stable disease had lower circulating activin A levels than the ones with progressive disease (P = .028). Conclusion: Activin A serum level could be used as a biomarker in differentiating malignant and benign lung tumors. Circulating activin A levels were elevated in MPM and associates with cancer cachexia and reduced chemotherapy response. (C) 2019 The Author(s). Published by Elsevier Inc. en
dc.format.extent 9
dc.language.iso eng
dc.relation.ispartof Clinical Lung Cancer
dc.rights cc_by_nc_nd
dc.rights cc_by_nc_nd
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3122 Cancers
dc.subject Mesothelioma
dc.subject NSCLC
dc.subject Biomarker
dc.subject Activin A
dc.subject Cancer cachexia
dc.subject Chemotherapy response
dc.subject SOLID TUMORS
dc.subject SARCOPENIA
dc.subject PROGNOSTIC VALUE
dc.subject BIOMARKERS
dc.subject SERUM CONCENTRATIONS
dc.subject CISPLATIN
dc.subject GROWTH
dc.subject MYOSTATIN
dc.subject FOLLISTATIN
dc.subject EXPRESSION
dc.title Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy en
dc.type Article
dc.contributor.organization Keuhkosairauksien yksikkö
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization INDIVIDRUG - Individualized Drug Therapy
dc.contributor.organization Research Programs Unit
dc.contributor.organization Faculty of Medicine
dc.contributor.organization HUS Heart and Lung Center
dc.contributor.organization Department of Surgery
dc.contributor.organization Clinicum
dc.contributor.organization III kirurgian klinikka
dc.contributor.organization Department of Diagnostics and Therapeutics
dc.contributor.organization University of Helsinki
dc.contributor.organization Sydän ja rintaelinkirurgia
dc.contributor.organization Department of Medicine
dc.contributor.organization Department of Pathology
dc.contributor.organization TRIMM - Translational Immunology Research Program
dc.contributor.organization HUSLAB
dc.contributor.organization Department of Physiology
dc.contributor.organization Growth factor physiology
dc.contributor.organization Katri Koli / Principal Investigator
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1016/j.cllc.2019.10.013
dc.relation.issn 1525-7304
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1525730419302876_main.pdf 1.095Mb PDF View/Open
PIIS1525730419302876.pdf 367.0Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record